中文
  • About Us
    Corporate Overview Management Team Board of Directors Contact Us
  • Our Focus
    Metabolic Diseases Exploratory Indications
  • Pipeline
    Pipeline Clinical Trials
  • Partnership
  • Investors
    Financials & Filing
  • News
  • Careers
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • Show More
    2014
  • Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist

    2025-03-31

  • Ascletis Pharma to Host Obesity Portfolio Webinar on April 2, 2025

    2025-03-20

  • Ascletis Announces Positive Topline Results of Phase Ib Studies of ASC47 Monotherapy in Australia and U.S. FDA Clearance of IND Application for ASC47 in Combination with Semaglutide

    2025-03-12

  • Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30

    2025-02-19

  • Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program Update

    2025-01-21

  • © 2018 Ascletis Pharma Inc.
  • All Rights Reserved

contact

  • pr@ascletis.com
  • bd@ascletis.com
  • hr@ascletis.com
  • clinicaltrials@ascletis.com

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号 浙ICP备11050387号-1